NCT01789099View on ClinicalTrials.gov

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 8, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

June 12, 2020

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

UV1 synthetic peptide vaccine and GM-CSF

Trial Locations (1)

0424

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

lead

Ultimovacs ASA

INDUSTRY

NCT01789099 - A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. | Biotech Hunter | Biotech Hunter